Karyopharm Therapeutics Inc  

(Public, NASDAQ:KPTI)   Watch this stock  
Find more results for KPTI
10.97
-0.04 (-0.36%)
Oct 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.89 - 11.16
52 week 6.27 - 14.63
Open 11.12
Vol / Avg. 82,679.00/223,859.00
Mkt cap 517.11M
P/E     -
Div/yield     -
EPS -2.70
Shares 47.14M
Beta 4.15
Inst. own 66%
Nov 6, 2017
Q3 2017 Karyopharm Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Sep 25, 2017
Karyopharm Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 6, 2017
Karyopharm Therapeutics Inc at Robert W Baird Gobal Healthcare Conference
Aug 9, 2017
Karyopharm Therapeutics Inc at Canaccord Genuity Growth Conference
Aug 8, 2017
Q2 2017 Karyopharm Therapeutics Inc Earnings Release
Aug 8, 2017
Q2 2017 Karyopharm Therapeutics Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -979566.70% -71153.90%
Operating margin -991733.30% -71903.90%
EBITD margin - -71438.31%
Return on average assets -69.10% -55.37%
Return on average equity -77.27% -60.77%
Employees 108 -
CDP Score - -

Address

85 Wells Ave
NEWTON CENTER, MA 02459-3298
United States - Map
+1-617-6580600 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1. The Company's lead drug candidate, selinexor (KPT-330), is an orally administered agent for the treatment of cancer indications with unmet clinical need, mainly hematologic malignancies. It is also engaged in the clinical development of selinexor in various solid tumor indications. Oral selinexor is being evaluated in multiple later-phase clinical trials in patients with relapsed and/or refractory hematological and solid tumor malignancies. Its lead drug candidate, oral selinexor (KPT-330), as well as verdinexor (KPT-335), KPT-8602 and KPT-9274 are in clinical development.

Officers and directors

Sharon Shacham Ph.D. President, Co-Founder, Chief Scientific Officer, Director
Age: 44
Bio & Compensation  - Reuters
Michael G. Kauffman M.D. Ph.D. Co-Founder, Chief Executive Officer and Director
Age: 52
Bio & Compensation  - Reuters
Michael Falvey Chief Financial Officer, Executive Vice President, Treasurer, Principal Financial Officer, Principal Accounting Officer
Age: 58
Bio & Compensation  - Reuters
Michael J. Todisco CPA Vice President - Finance, Assistant Treasurer
Age: 52
Bio & Compensation  - Reuters
Christopher B. Primiano Vice President- Corporate Development, General Counsel, Secretary
Age: 35
Bio & Compensation  - Reuters
Dilara McCauley Ph.D. Vice President - Product Leadership
Bio & Compensation  - Reuters
Brian Austad Ph.D. Senior Director, Head - Pharmaceutical Sciences
Bio & Compensation  - Reuters
Ran Frenkel Chief Development Operations Officer
Age: 46
Bio & Compensation  - Reuters
Barry E. Greene Lead Independent Director
Age: 53
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. Director
Age: 58
Bio & Compensation  - Reuters